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credited.SUMMARY
Toxic liver injury is a leading cause of liver failure and
death because of the organ’s inability to regenerate
amidst massive cell death, and few therapeutic
options exist. Themechanisms coordinating damage
protection and repair arepoorly understood.Here,we
show that S-nitrosothiols regulate liver growth during
development and after injury in vivo; in zebrafish,
nitric-oxide (NO) enhanced liver formation indepen-
dently of cGMP-mediated vasoactive effects. After
acetaminophen (APAP) exposure, inhibition of the
enzymatic regulator S-nitrosoglutathione reductase
(GSNOR) minimized toxic liver damage, increased
cell proliferation, and improved survival through sus-
tained activation of the cytoprotective Nrf2 pathway.
Preclinical studies of APAP injury in GSNOR-deficient
mice confirmed conservation of hepatoprotective
properties of S-nitrosothiol signaling across verte-
brates; a GSNOR-specific inhibitor improved liver
histology and acted with the approved therapy
N-acetylcysteine to expand the therapeutic time
windowand improveoutcome.Thesestudiesdemon-
strate that GSNOR inhibitors will be beneficial thera-
peutic candidates for treating liver injury.
INTRODUCTION
Acetaminophen (APAP) is the most widely used analgesic in
the United States and the most common cause of acute liver56 Cell Reports 6, 56–69, January 16, 2014 ª2014 The Authorsfailure (Bernal et al., 2010), caused by oxidative stress and
necrosis (Jaeschke et al., 2012). The only available therapy is
the antidote N-acetylcysteine (NAC). However, its use is limited
to the first few hours after ingestion, and delayed treatment
further increases mortality (Craig et al., 2012). Consequently,
there is an unmet clinical need for therapeutic options for
treating toxic liver injury. Compounds that exploit the liver’s
remarkable capacity to regenerate, rather than prevent toxic
effects, may provide therapeutic opportunities for treating toxic
liver injury.
Many of the signaling pathways involved in liver repair also
play a critical role in the formation of liver progenitors and in
liver growth during development (Goessling et al., 2008; Lade
and Monga, 2011). The zebrafish has recently emerged as an
attractive system to study liver development and regeneration,
given that many of the molecular programs are highly
conserved with mammals (Chu and Sadler, 2009). Further, we
established a clinically relevant model of APAP-induced liver
toxicity in zebrafish (North et al., 2010) and developed surgical
resection models to study liver regeneration (Goessling et al.,
2008; Sadler et al., 2007). In order to identify regulators of
hepatic growth that could lead to therapeutic approaches for
patients with liver failure, we conducted a chemical genetic
screen for modifiers of liver development in vivo (Garnaas
et al., 2012) using zebrafish and identified compounds targeting
nitric oxide (NO) regulation.
NO is a well-characterized signaling molecule that plays a
crucial role in regulating vasodilation and angiogenesis. NO
can regulate signaling pathways by two distinct mechanisms.
The best-known action of NO is to activate soluble guanylate
cyclase, which causes cGMP accumulation and vasodilation
(Murad, 2006). Many biological effects of NO, however,
Figure 1. NO Signaling Regulates Liver Size during Development in Zebrafish
(A) Effect of chemical modulators of NO signaling on liver formation. Zebrafish were exposed to chemicals (10 mM) from 24 to 72 hpf and subjected to in situ
hybridization for the hepatocyte gene lfabp. Representative photomicrographs were taken at 103 magnification.
(B) Effect of drug treatment on liver size in Tg(lfabp:GFP) embryos. Representative fluorescent photomicrographs were taken at 103 magnification.
(C) Phenotypic analysis of liver size as determined by lfabp in situ hybridization in treated embryos at 72 hpf (S, small; M, medium; L, large, n > 50 embryos per
treatment).
(D) Effect of drug treatment on the percentage of hepatocytes specified during liver formation. Chemically treated Tg(lfabp:GFP) embryos were dissociated and
the percentage of GFP positive hepatocytes was analyzed by fluorescence-activated cell sorting (FACS). n = 4; ANOVA, *p < 0.05 in comparison to control.
(E and F) Effect of drug treatment on hepatic progenitor cells. Zebrafish embryos were exposed to chemicals (10 mM) from 18 to 36 hpf or 24–48 hpf and subjected
to in situ hybridization for the endodermal genes hhex and foxA3, respectively.
(G and H) Phenotypic analysis of hepatic bud size as determined by hhex and foxA3 in situ hybridization in treated embryos at 36 and 48 hpf, respectively (n > 25
embryos per treatment).
(I) Effect of drug treatment on hepatic progenitor cell proliferation as determined by BrdU incorporation or pH 3 staining, respectively.
(J and K) Quantification of hepatic progenitor cell proliferation.
Representative photomicrographs were taken and cell counts were performed. n = 10; ANOVA, *p = 0.042, **p < 0.001 in comparison to control. Results in (D), (J),
and (K) show mean ± SEM.
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Figure 2. Constitutive NOS Activity Is
Required for Optimal Liver Development
(A) Effect of morpholino-mediated knockdown of
nos1 and nos2 gene expression on liver formation
as assessed by in situ hybridization for lfabp at
72 hpf. Translation blocking ATG morpholinos
against nos 1 and 2 were injected at a concen-
tration of 50 mM. Representative photomicro-
graphs were taken at 103 magnification.
(B) Effect of nos knockdown on liver size
in Tg(lfabp:GFP) embryos. Representative fluo-
rescent photomicrographs were taken at 103
magnification.
(C) Effect of nos knockdown on hepatic progenitor
cells as assessed by in situ hybridization for foxA3
at 48 hpf. Representative photomicrographs were
taken at 103 magnification.
(D) Phenotype analysis of liver size (lfabp) in mor-
phants at 72 hpf (n > 50 embryos per treatment).
(E) Effect of nos knockdown on the percentage of
hepatocytes specified during liver formation.
Tg(lfabp:GFP) morphants were dissociated, and
the percentage of GFP positive hepatocytes was
analyzed by FACS.
n = 8; ANOVA, *p = 0.033 in comparison to control.
Results in (E) show mean ± SEM.occur via a second mechanism involving direct binding of
NO to cysteine residues of proteins to form S-nitrosothiols
(S-nitrosylation), which can alter protein function and modulate
signaling pathways (Lima et al., 2010). S-nitrosoglutathione
(GSNO), the primary S-nitrosothiol, is catabolized in vivo by the
enzyme GSNO reductase (GSNOR). Despite the wealth of
knowledge regarding NO function in the vasculature, the involve-
ment of NO regulation in liver development has not been
examined.
The role of NO signaling in the context of liver injury has been
controversial. Studies have shown that nitric oxide synthase 2
(Nos2, inducible isoform) is induced by APAP, and that nitrosa-
tive stress, as measured by nitrotyrosine, is increased in the cen-
trilobular region of the liver (Hinson et al., 1998; Knight et al.,
2001; Saito et al., 2010). Furthermore, mice deficient in either
Nos1 (neuronal isoform) or Nos2 are protected from APAP, sug-58 Cell Reports 6, 56–69, January 16, 2014 ª2014 The Authorsgesting that the Nos isoforms may exac-
erbate liver injury (Agarwal et al., 2012;
Michael et al., 2001). However, there is
also evidence that NO signaling can be
beneficial in the setting of ischemia-
reperfusion injury (Cottart et al., 1999;
Elrod et al., 2008) or during liver regener-
ation following partial hepatectomy
(Kurokawa et al., 2012; Mei and Theva-
nanther, 2011; Rai et al., 1998). Given
these opposing results, a more detailed
understanding of the functional role of
NO signaling in liver injury, particularly
during toxic insults, is needed.
In the present study, we discover that
chemical modulators of NO signalingcan regulate liver formation. Increased NO levels enhanced
the proliferation of hepatic progenitor cells via a cGMP-indepen-
dent mechanism involving S-nitrosylation. GSNOR inhibition,
which enhances S-nitrosothiol signaling, activated the Nrf2
antioxidant response pathway, which enhanced survival in
zebrafish exposed to APAP. In addition to its effects after toxic
injury, GSNOR inhibition enhanced liver regrowth following
partial hepatectomy. The effects of GSNOR were found to
be evolutionarily conserved as GSNOR-deficient mice were
similarly protected from APAP-induced liver injury. Finally, in
translational experiments, we demonstrated the therapeutic
potential of a chemical GSNOR inhibitor, N6547, which syner-
gized with NAC to protect wild-type mice from APAP-induced
liver injury. These findings demonstrate the great therapeutic
promise of GSNOR inhibitors in protecting from liver injury and
promoting organ repair.
Figure 3. NO Signaling Regulates Liver Size in a cGMP-Independent Manner Involving Modulation of S-Nitrosothiol Homeostasis
(A) Effect of chemical modulators of NO signaling on liver formation in cloche mutants that lack a vasculature. Cloche mutants and siblings (sib) were exposed to
chemicals (5 mM) from 24 to 72 hpf and subjected to in situ hybridization for the hepatocyte gene lfabp. Representative photomicrographs were taken at 103
magnification.
(B andC) Phenotype analysis of liver size inWT and clochemutants exposed to the cGMP analog, 8BrGMP (10 mM), or the S-nitrosothiol GSNO (10 mM) from 24 to
72 hpf as determined by in situ hybridization for lfabp (n > 25 embryos per treatment).
(legend continued on next page)
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RESULTS
NO Signaling Regulates Liver Size during Development
in Zebrafish
We previously performed a chemical genetic screen for modula-
tors of liver formation in zebrafish embryos at 72 hr postfertiliza-
tion (hpf) (Garnaas et al., 2012) and identified compounds that
impact NO production and signaling. To confirm the screening
results, we examined the effect of well-established modulators
of NO signaling on liver formation: exposure to the NO precursor,
L-arginine (L-Arg, 10 mM), or the NO donor diethylenetriamine-
NONOate (Deta, 10 mM) from 24–72 hpf increased liver size, as
determined by in situ hybridization for the hepatocyte-specific
genes liver fatty acid binding protein (lfabp) and transferrin
(Figures 1A, S1A, and S2B). Incubation with the NOS inhibitors,
L-NG-Nitroarginine methyl ester (L-NAME, 10 mM) or NG-
amino-L-arginine (L-NMMA, 10 mM) from 24 to 72 hpf decreased
liver size. The contrasting effects of L-Arg and L-NAME on liver
formation were confirmed by in vivo fluorescent microscopy of
lfabp:GFP transgenic zebrafish (Figure 1B). Of embryos exposed
to L-Arg, 51% had a large liver, whereas L-NAME treatment
diminished liver size in 62% of embryos examined (Figure 1C).
Flow cytometric analysis of GFP+ cells in lfabp:GFP embryos
quantified the effects of L-Arg (37% increase) and L-NAME
(39% decrease) on hepatocyte number (Figure 1D). Chemical
modulation of NO signaling did not affect the formation of other
endodermal organs as determined by in situ hybridization for
foxA3 (pan-endoderm), trypsin (exocrine pancreas), insulin
(endocrine pancreas), and ifabp (gut). Similarly, heart formation
(cmlc2), a known target tissue for NO modulation, was not
affected by NO signaling (Figure S1C). Altogether, these studies
demonstrate that NO signaling specifically regulates liver growth
during development.
We further studied the temporal requirements for NO
signaling during liver development. NO caused dramatic
changes in liver formation after exposure from 24 to 48 hpf
when liver progenitors are being formed (Figure S1D); however,
no changes in liver size were observed after treatment from 48
to 72 hpf during hepatocyte differentiation (Figure S1E). The
effect of NO on hepatic progenitors was examined with the
early hepatic progenitor/endoderm markers hhex, prox1, and
foxA3. L-Arg increased hepatic bud size (hhex and prox1) at
36 hpf in 26% (Figures 1E, 1G, S1F), and foxA3 expression at
48 hpf in 51% of embryos (Figures 1F and 1H). In contrast,
L-NAME substantially diminished hepatic bud size. Bromo-
deoxyuridine (BrdU) incorporation or staining for the mitotic
marker pH3 indicated that L-Arg increased hepatic prolifera-
tion, whereas L-NAME inhibited cell-cycle progression (Figures
1I–1K). Alogether, these data demonstrate that NO enhances
hepatic progenitor proliferation during development.(D) Effect of chemical inhibition ormorpholino-mediated knockdown of GSNORon
72 hpf. The translation blocking ATGmorpholino against GSNORwas injected at a
magnification.
(E) Phenotype analysis of liver size in GSNOR-deficient embryos at 72 hpf as de
(F) Loss of GSNOR function alters the percentage of hepatocytes specified during
of GFP positive hepatocytes was analyzed by FACS.
n = 4; ANOVA, *p = 0.041, **p = 0.002 in comparison to control. Results in (F) sh
60 Cell Reports 6, 56–69, January 16, 2014 ª2014 The AuthorsTo genetically confirm the role of NO signaling in liver develop-
ment, liver formation was assessed after morpholino mediated
knockdown of nos1 and nos2. Knockdown of nos1 severely
inhibited liver formation, whereas knockdown of nos2 had no
effect (Figures 2A, 2B, and S2A). Knockdown of nos1, but not
nos2, also caused significant reduction in hepatic progenitors
at 48 hpf (Figure 2C). These specific effects of nos1 knockdown
were quantified by phenotypic analysis of liver size (Figures 2D
and S2B) and flow cytometric analysis of lfabp:GFP morphants
(Figure 2E). Together, these results indicate that nos1 is required
for optimal liver formation.
S-Nitrosothiol Signaling Regulates Liver Formation
Independently of cGMP
NO signaling can occur via two distinct mechanisms, namely,
cGMP-dependent vasodilation and S-nitrosylation pathways.
In order to clarify the importance of the well-known vascular
effects of NO mediated by cGMP, we examined the impact of
chemical modulators of NO signaling in cloche mutants that
have no endothelial cells and therefore lack any vasculature.
Exposure to L-Arg increased liver size in 37% of treated cloche
embryos, whereas 40% of L-NAME treated cloche embryos had
a smaller liver (Figures 3A–3C). Similarly, exposure of embryos
to a cGMP analog (8BrGMP, 10 mM) had no effect on liver
size, whereas the S-nitrosothiol S-nitrosoglutathione (GSNO,
5 mM) increased liver size in 41% of wild-type and 43% of
cloche embryos (Figures 3A–3C). Together, these results
demonstrate that NO signaling regulates liver size by S-nitroso-
thiol signaling independently of cGMP-mediated effects on the
vasculature.
GSNOR is a highly conserved enzyme (Figure S3A) that
metabolizes S-nitrosothiols and thereby negatively regulates
S-nitrosothiol signaling. Embryos exposed to the specific
GSNOR inhibitor N6547 (GSNORi, 1 mM, N30 Pharmaceuticals)
from 24 to 72 hpf exhibited a dramatic increase in liver size in
40% of the embryos examined (Figures 3D, 3E, S3B, and
S3C). Similarly, morpholino-mediated knockdown of GSNOR
caused an enlarged liver in 51% of embryos (Figures 3D and
3E). GSNORi exposure from 24 to 48 hpf also increased hepatic
bud size (sid4) (Figure S3D). Flow cytometry of GSNORi-treated
or GSNOR-deficient lfabp:GFP embryos confirmed increased
hepatocyte number (Figure 3F). Together, these findings demon-
strate that enhanced S-nitrosothiol signaling due to GSNOR
inhibition enhances growth in the developing liver.
GSNOR Inhibition Is Hepatoprotective and Enhances
Survival in Embryos Exposed to APAP via Activation of
the Nrf2 Pathway
Given the positive effects of S-nitrosothiol signaling on hepatic
growth during development, we examined whether GSNORiliver size as determined by in situ hybridization for the hepatocyte gene lfabp at
concentration of 50 mM. Representative photomicrographs were taken at 103
termined by in situ hybridization for lfabp (n > 25 embryos per treatment).
liver formation. Tg(lfabp:GFP)morphants were dissociated and the percentage
ow mean ± SEM.
Figure 4. GSNOR Inhibition Is Hepatoprotective and Enhances Survival in Embryos Exposed to APAP via Activation of the Nrf2 Pathway
(A) Effect of GSNORi and NAC on recovery from APAP-induced liver injury in Tg(lfabp:GFP) embryos. Tg(lfabp:GFP) embryos were exposed to a sublethal dose of
APAP (5 mM) from 48 to 60 hpf at which point embryos were washed and subsequently exposed to GSNORi (1 mM) and/or NAC (10 mM) from 60 to 96 hpf.
Representative fluorescent photomicrographs were taken at 103 magnification.
(B) Survival in embryos exposed to a lethal dose of APAP (10 mM) from 48 to 96 hpf in the presence or absence of L-NAME (10 mM), GSNORi (1 mM), and NAC
(10 mM). Under some conditions treatments were given after a 12 hr delay (del). n = 150; Fisher’s exact test, *p < 0.001 compared to APAP alone, **p < 0.001
compared to APAP + NAC.
(legend continued on next page)
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improved outcome in a zebrafish model of acetaminophen
(APAP)-induced liver injury (North et al., 2010). Transgenic
lfabp:GFP embryos were exposed to a sublethal dose of APAP
(5 mM) from 48 to 60 hpf, followed by treatment with L-NAME,
GSNORi, and/or NACduring the recovery phase (60–96 hpf) (Fig-
ure 4A). APAP decreased liver size, and this reduction was exac-
erbated by L-NAME. In contrast, either NAC (10 mM) or GSNORi
alone rescued liver size in APAP exposed embryos and acted
synergistically to further stimulate hepatic repair. A lethal dose
of APAP (10 mM) from 48 to 96 hpf caused a dramatic reduction
in survival (Figure 4B, 4%). Treatment with GSNORi or NAC alone
significantly increased survival to 32%, and combination therapy
further improved survival to 49%. When GSNORi or NAC was
given alone after a 12 hr delay to model a scenario often encoun-
tered in clinical practice, there was a modest increase in survival
(18% and 15%, respectively); in contrast, combined treatment
led to a doubling in survival rates (31%). In addition to GSNORi,
cotreatment with the NO donors Deta and GSNO also protected
from APAP-induced liver toxicity and improved survival (Figures
S4A and S4B). In order to further investigate the proproliferative
effect of treatments following APAP-induced liver injury, BrdU
incorporation was examined during the recovery phase (Fig-
ure 4C). APAP exposure decreased the number of BrdU-positive
cells, and this was further decreased by incubation with L-NAME
(Figures 4C and 4D). GSNORi or NAC exposure increased BrdU
incorporation, and the compounds together dramatically
increased BrdU-positive cell number in the regenerating liver
(Figures 4C and 4D). Together, these studies demonstrate that
GSNORi may work in a synergistic or additive fashion with
NAC to prevent APAP toxicity, stimulate organ repair, and
enhance survival.
To identify the mechanism by which GSNORi enhances sur-
vival, we investigated whether S-nitrosothiol signaling activated
the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway,
which plays a pivotal role in the cell’s adaptive response to stress
(Taguchi et al., 2011). Exposure to GSNORi alone from 48 to 54
hpf induced hepatic expression of the nrf2 target prdx1 (Fig-
ure 4E). Further, nrf2 knockdown prevented this GSNORi-
dependent induction of prdx1, indicating regulation of the
Nrf2 pathway by S-nitrosothiol signaling. To demonstrate the
response of Nrf2 signaling to toxic stress, zebrafish were
exposed to APAP, which caused a dramatic increase in Nrf2-
dependent expression of prdx1 and hmox 1 both in the presence
or absence of GSNORi at 54 and 72 hpf (Figures 4E, S4C, and
S4D). Nrf2 signaling was essential for survival, because nrf2
morphants were highly sensitive to APAP toxicity compared to
control-injected siblings (Figure 4F). More importantly, the
therapeutic effect of GSNORi on survival was abated in nrf2
morphants. Together, these studies demonstrate that the hepa-(C) Effect of GSNORi and NACon proliferation following APAP-induced liver injury.
which point embryos were washed and subsequently exposed toGSNORi (1 mM) a
BrdU just prior to fixation. Representative photomicrographs were taken at 103
(D) Quantification of BrdU positive cells in the regenerating liver of APAP exposed
in comparison to APAP alone.
(E) Effect of GSNORi (1 mM) and/or APAP (5 mM) exposure from 48 to 54 hpf on i
Translation blocking ATG morpholino against nrf2 was injected at a concentratio
(F) Survival in WT embryos and nrf2 morphants exposed to a lethal dose of APA
n = 75; Fisher’s exact test, **p = 0.012. Results in (D) show mean ± SEM.
62 Cell Reports 6, 56–69, January 16, 2014 ª2014 The Authorstoprotective properties of GSNORi in APAP-induced liver injury
are mediated by the Nrf2 pathway.
GSNOR Inhibition Protects Adult Zebrafish from APAP-
Induced Toxicity and Enhances Regeneration following
Liver Resection
Having shown that S-nitrosothiol signaling was hepatoprotective
and proregenerative in APAP-exposed larvae, we examined
whether GSNORi remained effective in adult zebrafish. Adult
transparent (casper) adult lfabp:GFP transgenic fish were
exposed to APAP in the presence or absence of GSNORi for
24 hr and examined at 72 hr postexposure (hpe) by in vivo fluo-
rescence microscopy. APAP exposure reduced GFP fluores-
cence, suggestive of hepatocyte necrosis, whereas coexposure
with GSNORi prevented loss in fluorescence (Figure 5A). Histo-
logically, GSNORi ameliorated hepatocellular necrosis (TUNEL
stain), sinusoidal widening, and hemorrhage (Figures 5B and
S5A). Circulating liver aminotransferase (ALT) levels in APAP-
exposed fish peaked at 24 hpe with 196 ± 35 U/l from a baseline
level of 47 ± 5 U/l, whereas GSNORi suppressed ALT levels to
55 ± 3 U/l (Figure 5C). Survival studies revealed that APAP
exposure caused a time-dependent loss in survival reaching
39% by 72 hpe; conversely, fish treated with GSNORi exhibited
a markedly enhanced survival rate of 65% by 72 hpe (Figure 5D).
Similarly, the NO donors Deta and GSNO increased overall
survival compared to APAP alone, whereas treatment with
L-NAME exacerbated death (Figure S5B). These results demon-
strate that GSNORi improves liver enzymes, histology, and sur-
vival after APAP exposure.
Treatment for APAP ingestion generally occurs after consider-
able delay in the clinical setting. Here, we tested whether
GSNORi remain beneficial when treatment was delayed. Treat-
ment with GSNORi or NAC alone after delay increased survival
at 72 hpe from 57% to 80% (Figure 5E). Combined treatment
with GSNORi and NAC, however, greatly enhanced survival
further to 95%. Immunohistochemical staining for PCNA after
delayed GSNORi treatment revealed that GSNORi stimulated
cell proliferation in the APAP-injured liver by 2-fold (Figures 5G
and S5A), demonstrating that it is not only hepatoprotective,
but also proproliferative as observed during development. To
test the requirement of the Nrf2 pathway, we exposed adult
nrf2 mutant zebrafish to APAP in the presence or absence of
GSNORi, which demonstrated that the nrf2mutants were highly
susceptible to APAP toxicity and they did not respond to
GSNORi treatment (Figures 5F and S5C). To directly examine
the proproliferative properties of GSNORi, we employed a surgi-
cal resection assay in adult zebrafish, removing the inferior lobe
of the liver and treating fish during the regenerative phase (Goes-
sling et al., 2008). GSNORi exposure significantly increased theEmbryos were exposed to a sublethal dose of APAP (5mM) from 48 to 60 hpf at
nd/or NAC (10 mM) from 60 to 96 hpf. Embryoswere pulsed for 10min in 10mM
magnification.
embryos exposed to GSNORi and/or NAC. n = 6; ANOVA, *p < 0.05, **p < 0.001
nduction of the Nrf2 target gene, prdx1, as determined by in situ hybridization.
n of 50 mM.
P (10 mM) from 48 to 80 hpf in the presence or absence of GSNORi (1 mM).
Figure 5. GSNOR Inhibition Protects Adult Zebrafish from APAP-Induced Toxicity and Enhances Regeneration following Liver Injury
(A) In vivo fluorescent imaging of the liver in adult casper Tg(lfabp:GFP) fish exposed to 10 mMAPAP for 18 hr before being exposed to GSNORi (1 mM). Adult fish
were anaesthetized at 72 hpe and immediately imaged by fluorescent microscopy. Representative fluorescent photographs were taken at 103 magnification.
(B) Hepatic histology (H&E) in fish exposed to APAP (10 mM) in the presence or absence of GSNORi (1 mM) at 48 hpe.
(C) Serum alanine aminotransferase (ALT) activity in fish exposed to APAP (10 mM) in the presence or absence of GSNORi (1 mM) at 24 or 72 hpe. n = 6; ANOVA,
*p < 0.05 in comparison to control.
(D) Kaplan-Meier plot of survival in adult fish exposed to APAP (10 mM) for 24 hr in the presence or absence of GSNORi (1 mM). Chemicals were removed 24 hpe,
fish were reintroduced into fresh water and survival was monitored over 72 hr. n = 45; Kaplan-Meier estimate, p = 0.0162, Cox regression hazard ratio (HR) = 1.95.
(legend continued on next page)
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length of regrowth in the inferior lobe at 3 dpr by 25% (Figures
5H, 5I, and S5E). Similarly, L-Arg increased the rate of liver
regeneration following partial hepatectomy, whereas L-NAME
diminished the regenerative response (Figures S5D–S5F).
Collectively, these data reveal that GSNORi is both hepatopro-
tective and proproliferative in the context of liver damage,
reducing toxicity, and promoting liver regeneration.
GSNOR-Deficient Mice Are Protected from APAP Injury
We next tested whether GSNOR-dependent hepatoprotection is
conserved in mice. WT and GSNOR KO C57Bl/6 mice were
injected with a sublethal dose of APAP (300 mg/kg) and exam-
ined at 6 and 24 hr. WT mice displayed significant centrilobular
hepatocyte necrosis coincident with increased TUNEL-positive
cells, whereas GSNOR KO mice showed a significant decrease
in hepatocellular necrosis at 6 and 24 hr (Figure 6A). The circu-
lating ALT values in APAP-injected WT mice increased to
1,431 ± 332 U/l at 6 hr and rose to 2,584 ± 299 U/l at 24 hr,
whereas GSNOR KO mice had markedly lower ALT values aver-
aging 543± 176U/l at 6 hr and 1,969± 227U/l at 24 hr (Figure 6B).
Quantification of liver necrosis from histological sections
confirmed that GSNOR-deficient mice were protected from
APAP (Figure 6C). Expression analysis of the APAP-metabolizing
enzyme Cyp2e1 by RT-PCR confirmed no differences between
WT and GSNOR KO mice, suggesting that the metabolic activa-
tion of APAP was not altered in the GSNOR-deficient mice (Fig-
ure S6). To see whether GSNOR-dependent regulation of the
Nrf2 pathway was conserved in mice, we monitored the nuclear
translocation of Nrf2, as an indication of Nrf2 activation, and
found that GSNOR KO mice exhibited a more sustained accu-
mulation of nuclear Nrf2 at 24 hr (Figures 6D and 6E). We exam-
ined expression of Nrf2 target genes by quantitative PCR
(qPCR), and this revealed sustained Hmox1 and Prdx1 induction
inGSNOR KOmice (Figures 6F and 6G). Together, these studies
demonstrate that the GSNOR regulation of the hepatoprotective
Nrf2 pathway is conserved across species.
Therapeutic Administration of GSNORi and NAC after
APAP Injury in Mice Indicates Significant Additive
Hepatoprotective Effects In Vivo
To directly evaluate the therapeutic properties of GSNORi in
translational studies in mammalian models, WT mice were
injected with a sublethal dose of APAP followed 2 hr later by
GSNORi (5 mg/kg) and/or NAC (300 mg/kg). Histological evalu-
ation showed that GSNORi provided a small yet significant level
of protection fromAPAP-induced centrilobular necrosis at both 6
and 24 hr (Figure 7A). As anticipated from clinical observations,
NAC prevented liver necrosis; however, the combination therapy(E) Kaplan-Meier plot of survival in adult fish exposed to APAP (10mM) for 18 hr fol
fish per treatment.
(F) Survival in adult WT fish and Nrf2 mutant fish exposed to APAP (10 mM) in th
(G) Hepatocyte proliferation was determined by immunohistochemical staining o
(10 mM) followed by delayed treatment with GSNORi (1 mM) at 48 hpe. n = 10; A
(H) Liver regeneration following partial hepatectomy in adult zebrafish at 3 days po
surgery for 24 hr. Representative en bloc dissection photographs were taken at
(I) Quantification of liver regeneration as determined by the length of regrowth fro
n = 20; ANOVA, **p < 0.001 in comparison to control. Results in (C), (G), and (I) s
64 Cell Reports 6, 56–69, January 16, 2014 ª2014 The Authorsof GSNORi and NACwas significantly more effective (Figure 7A).
GSNORi or NAC alone reduced circulating ALT to 72% and 43%
of the level of APAP alone, respectively, whereas GSNORi and
NAC combined reduced ALT levels to 25% of the level of
APAP alone (Figure 7B). The extent of liver necrosis reflected
the differences seen in serumALT values, with GSNORi reducing
liver necrosis, particularly when combined with NAC (Figure 7C).
Collectively, these experiments reveal that GSNORi acts in
combination with NAC to protect mice after APAP exposure,
highlighting the therapeutic potential of GSNORi in toxic liver
injury.
DISCUSSION
In this study, we identified NO and S-nitrosothiol signaling as
critical regulators of hepatic growth during development and
following toxic liver injury. Originating from its discovery as a
modulator of organ development in a chemical genetic screen,
we demonstrate the conserved action of S-nitrosothiol signaling
as a proproliferative and hepatoprotective pathway. Importantly,
we reveal the therapeutic potential of GSNOR inhibitors in
preclinical zebrafish and murine models of toxic and surgical
liver injury.
S-Nitrosothiol Signaling Is a Universal Injury Response
Pathway
The role of S-nitrosothiols may extend beyond the liver as a
universal response to injury. Most forms of liver injury, including
partial hepatectomy (Ronco et al., 2004), APAP (Hinson et al.,
1998; Knight et al., 2001; Saito et al., 2010), thioacetamide
(Dı´ez-Ferna´ndez et al., 1997), carbon tetrachloride (Mizumoto
et al., 1997), or ethanol exposure (Venkatraman et al., 2004),
lead to iNOS induction, suggesting that NO and S-nitrosothiol
signaling may be universal components of the stress response
in the liver. From a teleological perspective, it would be logical
for an organism to respond to injury by inducing expression of
enzymeswhose products play an integral role in the regenerative
response. The cytoprotective properties of S-nitrosothiol
signaling are not limited to the liver, as previous work has shown
thatGSNOR-deficient mice are protected frommyocardial injury
(Lima et al., 2009), indicating that S-nitrosothiol signaling may
play an important role in the injury response. Comparative
studies in sunflower seedlings and Arabidopsis thaliana demon-
strate that mechanical wounding downregulates GSNOR and
provokes an increase in S-nitrosothiols, which are necessary
for an appropriate response to injury (Chaki et al., 2011; Espunya
et al., 2012). Together, these studies suggest that GSNOR-
dependent S-nitrosothiol signaling may be a phylogeneticallylowed by a delayed treatment with GSNORi (1mM) and/or NAC (10mM). n > 20
e presence or absence of GSNORi (1 mM) for 18 hr. n > 17 fish per treatment.
f PCNA positive hepatocytes in liver sections from WT fish exposed to APAP
NOVA, **p < 0.001.
st resection (dpr). Adult fishwere exposed to DMSOor GSNORi (1 mM) 6 hr after
2.53 magnification.
m the resection margin divided by the total length of the inferior lobe.
how mean ± SEM.
Figure 6. GSNOR Deficiency Protects Mice from APAP Injury
(A) Hepatic histology in WT and GSNOR KO mice injected with a sub-lethal dose of APAP (300 mg/kg) at 6 or 24 hpe. Mice were sacrificed at 6 or 24 hpe. Livers
were sectioned and stained with H&E in conjunction with TUNEL stain in order to highlight centrilobular necrosis. Representative sections were taken at 103
magnification. n = 4–5 mice per group.
(B) Serum alanine aminotransferase (ALT) activity in WT and GSNOR KO mice injected with APAP (300 mg/kg) at 6 or 24 hpe. n = 4–5; ANOVA, **p < 0.05.
(C) Quantification of liver necrosis in histological sections of WT or GSNOR KO mice injected with APAP (300 mg/kg) at 6 or 24 hpe. Areas of necrosis were
highlighted and quantified using ImageJ software. n = 4–5; ANOVA, **p < 0.01.
(legend continued on next page)
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conserved and universal mechanism across kingdoms by which
multicellular organisms respond to and recover from injury.
S-Nitrosothiol Signaling Orchestrates Protective and
Proliferative Pathways after Injury
Our data revealed that the hepatoprotective properties of
GSNOR inhibition were due at least in part to activation of the
Nrf2 pathway. Nrf2 reacts to xenobiotic stress by inducing pro-
duction of proteins that promote detoxification and cytoprotec-
tion (Taguchi et al., 2011); this mechanism is highly conserved
in zebrafish (Kobayashi et al., 2009; Mukaigasa et al., 2012). Pre-
vious studies in mice have shown that Nrf2 activation protects
from APAP injury (Okawa et al., 2006), whereas Nrf2 deficiency
sensitizes mice to APAP toxicity (Chan et al., 2001; Enomoto
et al., 2001) and impairs liver regeneration following partial
hepatectomy (Beyer et al., 2008; Wakabayashi et al., 2010).
Our data demonstrate that, in contrast to exogenous activators
of the Nrf2 pathway, GSNOR inhibition may lead to transient
nitrosylation of the Nrf2 binding partner Keap1, thereby ampli-
fying the availability of Nrf2. GSNOR inhibitors therefore may
play an important role in regulating the Nrf2 activation threshold
and extending the duration of the injury response.
Although our studies focused on the GSNOR-mediated regu-
lation of the Nrf2 pathway, GSNOR likely regulates the activity of
additional regenerative pathways through nitrosylation of other
protein targets. For example, Snyder and colleagues have
shown that S-nitrosylation of Cox-2 enhances PGE2 production
(Kim et al., 2005), which is intriguing, because we have previ-
ously shown that PGE2 is hepatoprotective in APAP-induced
liver injury (North et al., 2010). There is also evidence that other
transcription factors, including Hif1a (Lima et al., 2009),
b-catenin (Thibeault et al., 2010), and NF-kB (Kelleher et al.,
2007; Sen et al., 2012), are subject to S-nitrosylation under
certain conditions. The transient nature of these nitrosylation
processes has posed a challenge for their detection, but may
represent a fast and highly flexible way to rapidly initiate and
terminate the desired regenerative effects. Consequently, one
could envisage a model in which iNOS induction during liver
injury facilitates the S-nitrosylation of numerous targets to coor-
dinate the regenerative response. Thus, GSNOR inhibition may
stimulate organ repair by orchestrating the activity of several
protective and proliferative pathways in unison (Figure S7).
GSNOR Inhibitors as Hepatoprotective Agents
We have demonstrated that a GSNOR inhibitor, N6547, can
protect from APAP-induced liver toxicity in vivo. Further, the
conserved effects in zebrafish and mice, the synergistic action
with the clinically used antidote NAC, and the widening of the
therapeutic time window, indicate the imminent translation
potential toward a clinical trial. The discovery that this NO-
induced process is distinct from the classic cGMP-dependent(D) Nuclear translocation of Nrf2 in the liver of WT and GSNOR KO mice as dete
(E) Quantification of nuclear Nrf2 in liver as determined by densitometry. n = 4; A
(F) Expression of the Nrf2 target gene Hmox-1 in liver as determined by qPCR inW
ANOVA, *p < 0.05 in comparison to control, **p < 0.001.
(G) Expression of the Nrf2 target gene Prdx-1 in liver as determined by qPCR in
n = 4–5; ANOVA, **p < 0.01. Results in (B), (C), and (E)–(G) show mean ± SEM.
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tion does not affect baseline blood pressure (Beigi et al., 2012;
Liu et al., 2004), which is often critically low in patients with liver
failure. Therefore, GSNOR inhibitors emerge as highly specific
drug candidates to provide enhanced hepatoprotection without
systemic side effects. To date, chemical screens in zebrafish
have led to clinical trials in blood stem cell therapy (Goessling
et al., 2011; North et al., 2007) and melanoma (White et al.,
2011). Here, we reveal a possible clinical application of GSNOR
inhibitors in regenerative medicine with the potential to extend to
other causes of liver failure and injury of other organs.
EXPERIMENTAL PROCEDURES
Zebrafish Husbandry
Zebrafish were maintained according to institutional animal care and use
committee (IACUC-BIDMC) protocols. Lines used in this study include wild-
type (AB), Tg(2.8fabp10:GFP)as3,mitfaw2/w2;roya9/a9;Tg(2.8fabp10:GFP)as3,
and nfe2l2a
fh318
as previously described (Her et al., 2003; Mukaigasa et al.,
2012; White et al., 2008).
Mice
C57BL/6 and GSNOR/ mice (Liu et al., 2004) were maintained in barrier
animal facilities. After overnight fasting, male mice were injected intraperitone-
ally with 300 mg/kg APAP dissolved in warm saline or saline alone. Mice were
injected intraperitoneally with chemical treatments (5 mg/kg GSNORi and/or
300 mg/kg NAC) dissolved in warm saline 1.5 hr after APAP injection. Mice
were sacrificed and blood and livers were harvested. Animal care and proce-
dures were reviewed and approved by the Harvard Medical School Standing
Committee on Animals.
Chemical Exposure
Embryos and adult zebrafish were exposed to L-arginine (L-Arg), D-arginine
(D-Arg), Deta-NONOate (Deta), L-NG-nitroarginine methyl ester (L-NAME),
L-NG-monomethyl Arginine citrate (L-NMMA), 8-bromoguanosine 30,50-
cyclic monophosphate sodium salt (8BrGMP), S-nitrosoglutathione (GSNO),
GSNORi (N6547, N30 Pharmaceuticals), and acetaminophen (APAP) as
described. Unless otherwise indicated, all chemicals were obtained from
Cayman Chemicals or Sigma-Aldrich.
Morpholino Injection
Validated morpholinos (MOs) (GeneTools) designed against the ATG and exon
1 splice site of nos1 (50-ACGCTGGGCTCTGATTCCTGCATTG-30; 50-TTAATG
ACATCCCTCACCTCTCCAC-30) (North et al., 2009), the ATG site of nos2
(50-AGTGGTTTGTGCTTGTCTTCCCATC-30) (North et al., 2009), the ATG site
of nrf2 (50-CATTTCAATCTCCATCATGTCTCAG-30 ) (Kobayashi et al., 2002),
the ATG site of gsnor (50-TGATCACTTTCCCAGTTGTGTCCAT-30) (this study)
or mismatched controls were injected into AB or Tg(2.8fabp10:GFP)as3
embryos at the one-cell stage.
In Situ Hybridization
Paraformaldehyde (PFA)-fixed embryos were processed for in situ hybridiza-
tion according to standard zebrafish protocols (http://zfin.org/). The following
RNA probes were used: lfabp, transferrin, foxa3, hhex, sid4, trypsin, insulin,
cmlc2, ifabp, prdx1, and hmox1. Changes in expression pattern (i.e., lfabp –
liver size) were typically scored as small, medium, or large. Expression
patterns represent the average of >50 embryos per treatment.rmined by immunoblot analysis.
NOVA, **p < 0.001.
T and GSNOR KOmice injected with APAP (300mg/kg) at 6 or 24 hpe. n = 4–5;
WT and GSNOR KO mice injected with APAP (300 mg/kg) at 6 or 24 hpe.
Figure 7. GSNORi and NAC Are Synergistically Hepatoprotective in APAP-Induced Liver Injury in Mice
(A) Hepatic histology in mice injected with a sublethal dose of APAP (300 mg/kg) followed by delayed (2 hpe) treatment with GSNORi (5 mg/kg) and/or NAC
(300 mg/kg). Mice were sacrificed at 6 or 24 hpe. Livers were sectioned and stained with H&E in conjunction with TUNEL stain in order to highlight centrilobular
necrosis. Representative sections were taken at 103 magnification. n = 4–5 mice per group.
(B) Serum alanine aminotransferase (ALT) activity in WT mice exposed to APAP (300 mg/kg) in the presence or absence of GSNORi (5 mg/kg) and/or NAC
(300 mg/kg) at 6 or 24 hpe. n = 4–5 mice per group.
(C) Quantification of liver necrosis in histological sections of WT mice injected with APAP (300 mg/kg) in the presence or absence of GSNORi (5 mg/kg) and/or
NAC (300 mg/kg) at 6 or 24 hpe. Areas of necrosis were highlighted and quantified using ImageJ software.
n = 4–5 mice per group. Results in (B) and (C) show mean ± SEM.Fluorescence Microscopy
Fluorescent liver reporter [Tg(2.8fabp10:GFP)as3] embryos or adults were
exposed to drugs as indicated, and microscopy was performed following
anesthesia with 0.04 mg/ml Tricaine-S.
Proliferation Assays
Proliferation was assessed in zebrafish embryos by whole-mount immuno-
histochemistry against either pH 3 or incorporated BrdU. In adult fish, cellproliferation was assessed in paraffin sections by performing immuno-
histochemistry against PCNA.
Fluorescence-Activated Cell Sorting Analysis
Fluorescent liver reporter (Tg(2.8fabp10:GFP)as3) embryos were dissoci-
ated by enzymatic disaggregation in TrypLE Express (Invitrogen) com-
bined with manual disruption. Upon addition of Dulbecco’s modified Eagle’s
medium with 10% FCS, the cells were strained through a 35 mM nylonCell Reports 6, 56–69, January 16, 2014 ª2014 The Authors 67
mesh and then analyzed using a BD FACSAria II flow cytometer
(BD Biosciences).
Histology
PFA-fixed fish or mice livers were paraffin embedded, cut into serial sections,
and stained with Hematoxylin and eosin (H&E) with standard techniques.
Partial Hepatectomy
Liver resections and regeneration analysis were conducted as described
previously (Goessling et al., 2008, 2009). Drug exposure occurred from 6 to
30 hr postresection (hpr), and liver regrowth was quantified in en bloc
dissected specimens at 3 dpr.
Serum ALT
Blood was collected from mice or zebrafish with a heparinized microcapillary
tube (Sarstedt) with standard methods (Retro-orbital or cardiac puncture).
Plasma ALT was measured using a microplate-based ALT activity assay kit
(Pointe Scientific).
Immunoblot analysis
Nuclear extracts were prepared frommice liver tissuewith the NE-PER nuclear
extraction kit according to the manufacturer’s directions (Pierce Biotech-
nology). Nuclear lysates were resolved by SDS-PAGE and electrophoretically
transferred onto nitrocellulose. Membranes were probed with anti-Nrf2
(Abcam) or antilamin A/C (Cell Signaling Technology) overnight and detected
with secondary antibody conjugated with HRP. Antibody complexes were
visualized by enhanced chemiluminescence using X-ray film. Nrf2 band inten-
sity was quantified using ImageJ.
qPCR Analysis
qPCR was performed using primer sets for murine hmox1, prdx1, gapdh,
b-actin, and cyp2e1 (Table S1). RNA was extracted from dissected liver with
Trizol (Invitrogen). qPCR was performed using SYBR Green Supermix
(QIAGEN) on the iQ5 Multicolor RTPCR Detection System (Bio-Rad).
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